Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2135406 | 0.91 | HCRTR2 (0.58) | HCRTR2HCRTR1 | |
| SCHEMBL2131256 | 0.91 | HCRTR2 (0.67) | HCRTR2HCRTR1 | |
| SCHEMBL2130860 | 0.91 | HCRTR2 (0.57) | HCRTR2HCRTR1 | |
| SCHEMBL2136349 | 0.84 | HCRTR2 (0.68) | HCRTR2HCRTR1 | |
| SCHEMBL6423312 | 0.84 | HCRTR2 (0.68) | HCRTR2HCRTR1 | |
| SCHEMBL2132291 | 0.83 | HCRTR2 (0.67) | HCRTR2HCRTR1 | |
| SCHEMBL6423720 | 0.80 | HCRTR2 (0.62) | HCRTR2HCRTR1 | |
| SCHEMBL2026638 | 0.79 | HCRTR2 (0.63) | HCRTR2HCRTR1 | |
| SCHEMBL2022233 | 0.79 | HCRTR2 (1.00) | HCRTR2HCRTR1 | |
| SCHEMBL2132500 | 0.79 | HCRTR2 (0.74) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281463-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | claimed |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | NOVARTIS PHARMA AG (CH) | 2012-04-26 | — | — | US | claimed |
| US-20130281463-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130281463-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130281463-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| EP-2632924-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012055888-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2012-05-03 | — | — | WO | disclosed |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | NOVARTIS PHARMA AG (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | NOVARTIS PHARMA AG (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | NOVARTIS PHARMA AG (CH) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281463-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY5R | HCRTR2 1/4885HCRTR1 2/4885 |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | REN, PKD1, NR3C2 | HCRTR2 3715/4885HCRTR1 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.